Pemetrexed, a novel antifolate therapeutic alternative for cancer chemotherapy

Pharmacotherapy

Volumn 26, Issue 5 I, 2006, Pages 641-654

  Villela, Leticia R ^a   Stanford, Brad L ^b   Shah, Sachin R ^a  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

Author keywords

Antifolate agent; Malignant pleural mesothelioma; MPM; Non small cell lung cancer; NSCLC; Pemetrexed

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTIEMETIC AGENT; CARBOPLATIN; CISPLATIN; CORTICOSTEROID; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DILUENT; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; ERLOTINIB; FLUOROURACIL; FOLIC ACID; FOLIC ACID ANTAGONIST; GEMCITABINE; IBUPROFEN; INTERFERON; INTERLEUKIN 2; LORAZEPAM; METHOTREXATE; METOCLOPRAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OXALIPLATIN; PEMETREXED; PLATINUM DERIVATIVE; PROCHLORPERAZINE; THYMIDINE; UNINDEXED DRUG;

ANEMIA; ANOREXIA; BONE MARROW SUPPRESSION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CYANOCOBALAMIN DEFICIENCY; DEHYDRATION; DIARRHEA; DRUG DISTRIBUTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; DRUG INCOMPATIBILITY; DRUG INTOXICATION; DRUG MECHANISM; DRUG METABOLISM; DRUG POTENTIATION; DRUG PROTEIN BINDING; DRUG RESPONSE; DRUG STORAGE; DRUG STRUCTURE; FATIGUE; FEBRILE NEUTROPENIA; FOLIC ACID DEFICIENCY; GASTROINTESTINAL SYMPTOM; HEAD AND NECK CANCER; HUMAN; INFECTION; KIDNEY CANCER; LEUKOPENIA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LUNG SMALL CELL CANCER; MONOTHERAPY; MUCOSA INFLAMMATION; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PLEURA MESOTHELIOMA; PREMEDICATION; RASH; REVIEW; SKIN TOXICITY; SOLID TUMOR; STOMACH CANCER; THROMBOCYTOPENIA; VITAMIN SUPPLEMENTATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II; DRUG INTERACTIONS; FOLIC ACID ANTAGONISTS; GLUTAMATES; GUANINE; HUMANS; NEOPLASMS;

EID: 33646338595     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.26.5.641     Document Type: Review

References (62)

1. Calvert H. Folate status and the safety profile of antifolates. Semin Oncol 2002;29(suppl 5):3-7.
2. Farber S, Diamond LK, Mercer RD, Sylvester RF, Wolff VA. Temporary remissions in acute leukemia in children produced by folic antagonist 4-amethopteroylglutamic acid (aminopterin). N Engl J Med 1948;238:787-93.
3. Berlin NI, Rail D, Mead JA, et al. Folic acid antagonist: effects on the cell and the patient. Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 1963;59:931-56.
4. Chu E, Mota AC, Fogarasi MC. Pharmacology of cancer chemotherapy: antimetabolites. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 6th ed. Philadelphia: Lippincott Williams & Wilkins, 1993:388-415.
5. Calvert AH. Biochemical pharmacology of pemetrexed. Oncology 2004;18(suppl 8):13-17.
6. Goldman ID, Zhao R. Molecular, biochemical, and cellular pharmacology of pemetrexed. Semin Oncol 2002;29(suppl 18)3-17.
7. Eli Lilly. Alimta (pemetrexed) package insert. Indianapolis, IN; 2005.
8. Hazarika M, White RM, Johnson JR, Pazdur R. FDA drug approval summaries: pemetrexed (Alimta). Oncologist 2004;9:482-8.
9. Adjei AA. Pemetrexed (Alimta): a novel multitargeted antifolate agent. Exp Rev Anticancer Ther 2003;3:145-56.
10. Shih C, Habeck LL, Mendelsohn LG, Chen VJ, Schultz RM. Multiple folate enzyme inhibition: mechanism of a novel pyrrolopyrimidine-based antifolate LY231514 (MTA). Adv Enzyme Regul 1998;38:135-52.
11. Messman RA, Allegra CJ. Antifolates. In: Chabner BA, Longo DL, eds. Cancer chemotherapy and biotherapy principles and practice, 3rd ed. Philadelphia: Lippincott Williams & Wilkins, 2001;8:139-84.
12. Zhao R, Goldman ID. Enter Alimta: a new generation antifolate. Oncologist 2004;9:242-4.
13. Wan SH, Huffman DH, Azarnoff DL, Stephens R, Hoogstraten B. Effect of route of administration and effusions on methotrexate pharmacokinetics. Cancer Res 1974;4:3487-91.
14. Castro M. Thymidine rescue: an antidote for pemetrexed-related toxicity in the setting of acute renal failure. J Clin Oncol 2003;21:4066-9.
15. Pass HI, Temeck BK, Kranda K, Steinberg SM, Feuerstein IR. Preoperative tumor volume is associated with outcome in malignant pleural mesothelioma. J Thorac Cardiovasc Surg 1998;115:310-18.
16. Sugarbaker DJ, Garcia JP, Richards WG, et al. Extrapleural pneumonectomy in the multimodality therapy of malignant pleural mesothelioma: results in 120 consecutive patients. Ann Surg 1996;224:288-96.
17. Maasilta P. Deterioration in lung function following hemithorax irradiation for pleural mesothelioma. Int J Radiat Oncol Biol Phys 1991;20:433-8.
18. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma: a review. J Clin Oncol 1996;14:1007-17.
19. Robinson B, Lake RA. Advances in malignant mesothelioma. N Engl J Med 2005;353:1591-603.
20. Byrne MJ, Davidson JA, Musk AW, et al. Cisplatin and gemcitabine treatment for malignant mesothelioma: a phase II study. J Clin Oncol 1999;17:25-30.
21. van Haarst JM, Baas P, Manegold CH, et al. Multicentre phase II study of gemcitabine and cisplatin in malignant pleural mesothelioma. Br J Cancer 2002;86:342-5.
22. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21:2636-44.
23. Niyikiza C, Hanauske AR, Rusthoven JJ, et al. Pemetrexed safety and dosing strategy. Semin Oncol 2002;29(suppl 18):24-9.
24. Jemal A, Murray T, Ward E, et al. Cancer statistics 2005. CA Cancer J Clin 2005;55:10-30.
25. Spira A, Ettinger DS. Drug therapy: multidisciplinary management of lung cancer. N Engl J Med 2004;350:379-92.
26. National Comprehensive Cancer Network. NCCN guidelines 2005: non-small cell lung cancer2E Available from http://www.nccn.org. Accessed May 29, 2005.
27. Schiller J, Harrington D, Belani CP, et al. Comparison of four chemotherapy regimens for advanced non-small cell lung cancer. N Engl J Med 2002;346:92-8.
28. Shepherd F, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000;18:2095-103.
29. Shepherd FA, Rodrigues PJ, Ciuleanu TE, et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005;353:123-32.
30. Hanna N, Shepherd FA, Fossella FV, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004;22:1589-97.
31. Rusthoven JJ, Eisenhauer E, Butts C, et al. Multitargeted antifolate LY231514 as first-line chemotherapy for patients with advanced non-small cell lung cancer: a phase II study. National Cancer Institute of Canada clinical trials group. J Clin Oncol 1999;17:1194-9.
32. Clarke SJ, Abratt R, Goedhals L, Boyer MJ, Millward MJ, Ackland SP. Phase II trial of pemetrexed disodium (Alimta, LY231514) in chemotherapy-naive patients with advanced non-small-cell lung cancer. Ann Oncol 2002;13:737-41.
33. Manegold C, Gatzemeier U, von Pawel J, et al. Front-line treatment of advanced non-small-cell lung cancer with MTA (LY231514, pemetrexed disodium, Alimta) and cisplatin: a multicenter phase II trial. Ann Oncol 2000;11:435-40.
34. Shepherd FA, Dancey J, Arnold A, et al. Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced non-small cell lung carcinoma: a study of the National Cancer Institute of Canada clinical trials group. Cancer 2001;92:595-600.
35. Scagliotti GV, Kortsik C, Dark GG, et al. Pemetrexed combined with oxaliplatin or carboplatin as first-line treatment in advanced non-small cell lung cancer: a multicenter, randomized, phase II trial. Clin Cancer Res 2005;11:690-6.
36. Gatzemeier U, Shepherd FA, LeChevalier T, et al. Activity of gemcitabine in patients with non-small cell lung cancer: a multicenter, extended phase II study. Eur J Cancer 1996;32A:243-8.
37. Manegold C, Bergman B, Chemaissani A, et al. Single-agent gemcitabine versus cisplatin-etoposide: early results of a randomized phase II study in locally advanced or metastatic non-small cell lung cancer. Ann Oncol 1997;8:525-9.
38. Cardenal F, Lopez-Cabrerizo MP, Anton A, et al. Randomized phase III study of gemcitabine-cisplatin versus etoposide-cisplatin in the treatment of locally advanced or metastatic non-small cell lung cancer. J Clin Oncol 1999;17:12-18.
39. Monnerat C, Le Chevalier T, Kelly K, et al. Phase 11 study of pemetrexed-gemcitabine combination in patients with advanced stage non-small cell lung cancer. Clin Cancer Res 2004;10:5439-46.
40. Adjei AA, Nair S, Reuter N, et al. Pemetrexed (Pem)/ gemcitabine (Gem) as front-line therapy for advanced NSCLC: a randomized, phase II trial of three schedules [abstr]. Proc Am Soc Clin Oncol 2004;23:630.
41. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alteration of these two regimens in extensive small cell lung cancer: a phase II trial of the southeastern cancer study group. J Clin Oncol 1992;10:282-91.
42. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small cell lung cancer. N Engl J Med 2002;346:85-91.
43. Socinski MA, Weissman C, Hart LL, et al. Randomized phase II trial of pemetrexed with either cisplatin or carboplatin in extensive stage small cell lung cancer [abstr]. Proc Am Soc Clin Oncol 2004;23:664.
44. Socinski MA. Pemetrexed (Alimta) in small cell lung cancer. Semin Oncol 2005;32(suppl 2):S1-4.
45. McDermott DF, Regan MM, Clark JI, et al. Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 2005;23:133-41.
46. Fyfe G, Fisher RI, Rosenberg SA, et al. Results of treatment of 255 patients with metastatic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 1995;13:688-96.
47. Negrier S, Escudier B, Lasset C, et al. Recombinant human interleukin-2, recombinant human interferon alfa-2a, or both in metastatic renal cell carcinoma. Groupe Français d'immunotherapie. N Engl J Med 1998;338:1272-8.
48. Thodtmann R, Sauter T, Weinknecht S, et al. A phase II trial of pemetrexed in patients with metastatic renal cancer. Invest New Drugs 2003;21:353-8.
49. National Comprehensive Cancer Network. NCCN guidelines 2005: breast cancer. Available from http://www.nccn.org. Accessed May 29, 2005.
50. Hortobagyi GN. Treatment of breast cancer. N Engl J Med 1998;339:974-84.
51. Martin M, Spielmann M, Namer M, et al. Phase II study of pemetrexed in breast cancer patients pretreated with anthracyclines. Ann Oncol 2003;14:1246-52.
52. Karpeh MS, Kelsen DP, Teppr JE. Cancer of the stomach. In: DeVita VT Jr, Hellman S, Rosenberg SA, eds. Cancer: principles and practice of oncology, 6th ed. Philadelphia: Lippincott, Williams & Wilkins, 2001:1092-126.
53. Bajetta E, Celio L, Buzzoni R, et al. Phase II study of pemetrexed disodium (Alimta) administered with oral folic acid in patients with advanced gastric cancer. Ann Oncol 2003;14:1543-8.
54. Dimery IW, Hong WK. Overview of combined modality therapies for head and neck cancer. J Natl Cancer Inst 1993;85:95-111.
55. Pivot X, Niyikiza C, Poissonnet G, et al. Multivariate analysis of prognostic factors in local recurrent and metastatic head and neck cancer: implication for clinical trials [abstr]. Proc Am Soc Clin Oncol 2000;19:414.
56. Pivot X, Raymond E, Laguerre B, et al. Pemetrexed disodium in recurrent locally advanced or metastatic squamous cell carcinoma of the head and neck. Br J Cancer 2001;85:649-55.
57. Scagliotti GV, Shin DM, Kindler HL, et al. Phase II study of pemetrexed with and without folic acid and vitamin B12 as front-line therapy in malignant pleural mesothelioma. J Clin Oncol 2003;21:1556-61.
58. Niyikiza C, Baker SD, Seitz DE. Homocysteine and methylmalonic acid: markers to predict and avoid toxicity from pemetrexed therapy. Mol Cancer Ther 2002;1:545-52.
59. Jacobs DS, Oxley KD, DeMott WR, eds. Homocysteine, plasma. In: Laboratory test handbook, 5th ed. Hudson: LexiComp Inc, 2001:193-5.
60. Trissel LA, Saenz CA, Ogundele AB, Ingram DS. Physical compatibility of pemetrexed disodium with other drugs during simulated Y-site administration. Am J Health-Syst Pharm 2004;61:2289-93.
61. Hesketh PJ, Kris MG, Grunberg SM, et al. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol 1997;15:103-9.
62. National Comprehensive Cancer Network. NCCN guidelines 2005: antiemesis. Available from http://www.nccn.org. Accessed May 29, 2005.